Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients

被引:20
作者
Vlek, A. L. M. [2 ]
van der Graaf, Y. [2 ]
Spiering, W. [1 ]
Visseren, F. L. J. [1 ]
机构
[1] UMC Utrecht, Sect Vasc Med, Dept Internal Med, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
关键词
metabolic syndrome; diabetes mellitus type II; cardiovascular diseases; epidemiology;
D O I
10.1038/jhh.2008.5
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Patients with hypertension and manifest vascular disease are at high risk for recurrent cardiovascular diseases. It is unknown if the metabolic syndrome further increases the risk in these patients. This study aims to quantify the effect of metabolic syndrome and type II diabetes on cardiovascular events in hypertensive patients with vascular disease. A total of 2196 hypertensive patients with vascular disease (cerebrovascular disease (34%), coronary heart disease (50%), peripheral arterial disease (28%), abdominal aortic aneurysm (13%)) from the Second Manifestations of Arterial Disease study were followed for up to 10 years (mean 3.9 years) for death, stroke and myocardial infarction. Age and sex adjusted hazard ratios (HR) were calculated for hypertensive patients with metabolic syndrome but without diabetes (n = 775) and for hypertensive patients with type II diabetes (n = 381), compared to merely hypertensive patients (n = 1040). Forty-nine percent had metabolic syndrome (NCEP ATPIII definition) and 17% had type II diabetes. Metabolic syndrome predicted vascular death (HR 1.41, 95% confidence interval (CI) 1.01-1.98), stroke (HR 1.36, 95% CI 0.85-2.16) and myocardial infarction (HR 1.40, 95% CI 0.97-2.01). Type II diabetes accounted for even higher risks of vascular end points (HR 1.41-1.64). The effect of metabolic syndrome on future events could not be explained by the presence of type II diabetes. Even in high-risk patients with hypertension and vascular disease, presence of metabolic syndrome or type II diabetes identifies patients at high risk for future cardiovascular events. Identifying metabolic syndrome patients may direct therapy focusing on treatment of insulin resistance by reducing weight and increasing physical activity.
引用
收藏
页码:358 / 365
页数:8
相关论文
共 36 条
  • [1] NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    Alexander, CM
    Landsman, PB
    Teutsch, SM
    Haffner, SM
    [J]. DIABETES, 2003, 52 (05) : 1210 - 1214
  • [2] The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death - A population-based study of 13000 men and women with 20 years of follow-up
    Almdal, T
    Scharling, H
    Jensen, JS
    Vestergaard, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (13) : 1422 - 1426
  • [3] Stroke and coronary heart disease in treated hypertension - a prospective cohort study over three decades
    Almgren, T
    Persson, B
    Wilhelmsen, L
    Rosengren, A
    Andersson, OK
    [J]. JOURNAL OF INTERNAL MEDICINE, 2005, 257 (06) : 496 - 502
  • [4] [Anonymous], 1994, CIRCULATION
  • [5] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [6] Metabolic syndrome and target organ damage in untreated essential hypertensives
    Cuspidi, C
    Meani, S
    Fusi, V
    Severgnini, B
    Valerio, C
    Catini, E
    Leonetti, G
    Magrini, F
    Zanchetti, A
    [J]. JOURNAL OF HYPERTENSION, 2004, 22 (10) : 1991 - 1998
  • [7] Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Deedwania, Prakash
    Barter, Philip
    Carmena, Rafael
    Fruchart, Jean-Charles
    Grundy, Scott M.
    Haffner, Steven
    Kastelein, John J. P.
    LaRosa, John C.
    Schachner, Holly
    Shepherd, James
    Waters, David D.
    [J]. LANCET, 2006, 368 (9539) : 919 - 928
  • [8] The metabolic syndrome
    Eckel, RH
    Grundy, SM
    Zimmet, PZ
    [J]. LANCET, 2005, 365 (9468) : 1415 - 1428
  • [9] Impact of metabolic syndrome on atherosclerotic burden and cardiovascular prognosis
    Espinola-Klein, Christine
    Rupprecht, Hans J.
    Bickel, Christoph
    Post, Felix
    Genth-Zotz, Sabine
    Lackner, Karl
    Munzel, Thomas
    Blankenberg, Stefan
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12) : 1623 - 1628
  • [10] Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
    Ford, ES
    Giles, WH
    Dietz, WH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03): : 356 - 359